Table 2

Outcomes compared between treatments

Outcomes	Groups	No.(%) of events or median difference		Unadjusted		Adjusted*		P_int† value
Outcomes	Groups	DAPT	Alteplase	Treatment difference (95% CI)	P value	Treatment difference (95% CI)	P value	P_int† value
Primary outcome
mRS 0–1 at 90 days‡ §	ACS	256/272 (94.1)	266/290 (91.7)	2.4 (−1.8 to 6.6)	0.27	1.8 (−1.2 to 4.9)	0.23	0.56
mRS 0–1 at 90 days‡ §	PCS	62/68 (91.2)	78/85 (91.8)	−0.6 (−9.5 to 8.3)	0.90	−2.8 (−9.0 to 3.5)	0.39	0.56
Secondary outcomes
mRS 0–2 at 90 days‡ §	ACS	261/272 (96.0)	277/290 (95.5)	0.4 (−2.9 to 3.8)	0.80	0.4 (−2.1 to 2.9)	0.75	0.97
mRS 0–2 at 90 days‡ §	PCS	62/68 (95.6)	81/85 (95.3)	0.3 (−6.3 to 6.9)	0.93	−0.8 (−5.4 to 3.9)	0.75	0.97
mRS distribution at 90 days‡¶	ACS	NA	NA	1.12 (0.77 to 1.62)	0.55	1.10 (0.85 to 1.42)	0.49	0.48
mRS distribution at 90 days‡¶	PCS	NA	NA	0.78 (0.36 to 1.65)	0.51	0.65 (0.38 to 1.09)	0.10	0.48
Early neurological deterioration within 24 hours**	ACS	13/274 (4.7)	23/292 (7.9)	−3.1 (−7.1 to 0.9)	0.12	−2.7 (−5.4 to 0.1)	0.06	0.79
Early neurological deterioration within 24 hours**	PCS	4/68 (5.9)	9/85 (10.6)	−4.7 (−13.3 to 3.9)	0.28	−4.9 (−10.9 to 1.2)	0.11	0.79
Early neurological improvement within 24 hours‡‡	ACS	37/274 (13.5)	70/292 (24.0)	−10.5 (−16.8 to -4.1)	<0.01††	−7.0 (−11.3 to -2.7)	<0.01††	0.71
Early neurological improvement within 24 hours‡‡	PCS	10/68 (14.7)	19/85 (22.4)	−7.6 (−19.9 to 4.6)	0.22	−2.7 (−11.1 to 5.6)	0.52	0.71
Change in NIHSS score at 24 hours§§	ACS	0.00 (−0.41 to 0.00)	0.00 (−0.69 to 0.00)	−0.10 (−0.19 to −0.01)	0.03††	−0.08 (−0.15 to −0.02)	0.01††	0.71
Change in NIHSS score at 24 hours§§	PCS	0.00 (−0.38 to 0.00)	0.00 (−0.69 to 0.00)	−0.06 (−0.21 to 0.08)	0.40	−0.06 (−0.16 to 0.05)	0.28	0.71
Stroke or other vascular events within 90 days¶¶	ACS	1/272 (0.4)	1/290 (0.3)	1.06 (0.07 to 16.96)	0.97	1.35 (0.08 to 23.84)	0.84	0.94
Stroke or other vascular events within 90 days¶¶	PCS	0/68 (0.0)	1/85 (1.2)	0.02 (0.00 to NA)	0.63	0.00 (0.00 to NA)	0.98	0.94
All-cause death at 90 days§	ACS	2/272 (0.7)	1/290 (0.3)	0.4 (−0.8 to 1.6)	0.53	0.3 (−0.5 to 1.2)	0.42	0.99
All-cause death at 90 days§	PCS	0/68 (0.0)	2/85 (2.4)	−2.4 (NA to NA)	0.20	−2.5 (NA to NA)	0.05	0.99
Safety outcomes
sICH§ ***	ACS	0/274 (0.0)	3/292 (1.0)	−1.0 (NA to NA)	0.09	−1.1 (NA to NA)	<0.01††	0.99
sICH§ ***	PCS	0/68 (0.0)	1/85 (1.2)	−1.2 (NA to NA)	0.37	−1.3 (NA to NA)	0.16	0.99
Bleeding events§†††	ACS	1/274 (0.4)	16/292 (5.5)	−5.1 (−7.8 to −2.4)	<0.01††	−5.3 (−7.2 to −3.3)	<0.01††	0.51
Bleeding events§†††	PCS	1/68 (1.5)	7/85 (8.2)	−6.8 (−13.3 to −0.3)	0.04††	−3.7 (−7.9 to −0.5)	0.03††	0.51

*Adjusted for participating centres and covariates compared between DAPT and alteplase treatments with p value<0.1 in each group in table 1.
†P value for interaction was calculated by adjusting covariates compared between ACS and PCS group with p value<0.1 in table 1.
‡mRS scores ranged from 0 to 6.
§Calculated using generalised linear model and presented by risk difference.
¶Calculated using ordinal regression analysis and presented by OR.
**Early neurological deterioration was defined as an increase between baseline and 24 hours of 2 on the NIHSS score, but not as a result of cerebral haemorrhage.
††P value<0.05.
‡‡Early neurological improvement was defined as a decrease between baseline and 24 hours of 2 on the NIHSS score.
§§NIHSS scores range from 0 to 42. Log (NIHSS+1) was analysed using generalised linear model and presented by geometric mean ratio.
¶¶Calculated using Cox regression model and presented by HR.
***Symptomatic intracranial haemorrhage was defined as any evidence of bleeding on head CT associated with neurological deterioration (NIHSS ≥4 point increase).
†††Bleeding events included symptomatic and asymptomatic intracerebral haemorrhage and gingival bleeding during the ARAMIS trial.
ACS, anterior circulation stroke; DAPT, dual antiplatelet therapy; mRS, modified Rankin Scale; N/A, not applicable; NHSS, National Institute of Health Stroke Scale; PCS, posterior circulation stroke; sICH, symptomatic intracranial haemorrhage.